Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 45, 2015 - Issue 2
555
Views
15
CrossRef citations to date
0
Altmetric
Research Article

Mass balance, pharmacokinetics and metabolism of the selective S1P1 receptor modulator ponesimod in humans

, , , , &
Pages 139-149 | Received 30 Jun 2014, Accepted 14 Aug 2014, Published online: 04 Sep 2014

References

  • Braley TJ, Segal BM. (2013). B-cell targeting agents in the treatment of multiple sclerosis. Curr Treat Options Neurol 15:259–69
  • Brossard P, Derendorf H, Xu J, et al. (2013). Phamacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol 76:888–96
  • Brossard P, Scherz M, Halabi A, et al. (2014). Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration. J Clin Pharmacol 54:179–88
  • Bruderer S, Hopfgartner G, Selbering M, et al. (2012). Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica 42:901–10
  • Cai Y, Flemming C, Yan J. (2012). New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol 9:302–9
  • International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (1996). Guideline for Good Clinical Practice CPMP, E6(R1), Geneva, Switzerland
  • International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). (2009). Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals, M3(R2), 5, Geneva, Switzerland
  • Olsson T, Boster A, Fernandez O, et al. (2014). Oral ponesimod in relapsing remeating multiple sclerosis: a randomized phase II trial. J Neurol Neurosurg Phsychiatry. [Epub ahead of print]. doi: 10.1136/jnnp-2013-307282
  • Piali L, Froidevaux S, Hass P, et al. (2011). The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther 337:574–56
  • Reyes M, Brossard P, Chassard D, et al. (2014). Effects of ponesimod, a selective S1P1 receptor modulator, on the pharmacokinetics of a hormonal combination contraceptive. Eur J Clin Pharmacol 70:287–93
  • Roffey SJ, Obach RS, Gedge JI, Smith DA. (2007). What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabelled drugs. Drug Metab Rev 39:17–43
  • Vaclavkova A, Chimenti S, Areberger P, et al. (2014). Efficacy, safety, and tolerability of ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. [Epub ahead of print]. doi: 10.1016/S0140-6736(14)60803-5

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.